Antiplatelet therapy after coronary stent placement in patients with atrial fibrillation

2014 ◽  
Vol 6 (3) ◽  
pp. 249-251
Author(s):  
Ion S Jovin
Keyword(s):  
Atrial Fibrillation ◽  
Antiplatelet Therapy ◽  
Stent Placement ◽  
Coronary Stent

scholarly journals Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review

2018 ◽  
Vol 7 (1) ◽  
Author(s):  
Christopher P. Childers ◽  
Melinda Maggard-Gibbons ◽  
Jesus G. Ulloa ◽  
Ian T. MacQueen ◽  
Isomi M. Miake-Lye ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cardiac Surgery ◽  
Antiplatelet Therapy ◽  
Stent Placement ◽  
Perioperative Management ◽  
Coronary Stent

scholarly journals Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

Thrombosis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Karl Mischke ◽  
Christian Knackstedt ◽  
Nikolaus Marx
Keyword(s):  
Atrial Fibrillation ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Oral Anticoagulation ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Risk Scores ◽  
Coronary Stent Implantation ◽  
Artery Disease

Anticoagulation represents the mainstay of therapy for most patients with atrial fibrillation. Patients on oral anticoagulation often require concomitant antiplatelet therapy, mostly because of coronary artery disease. After coronary stent implantation, dual antiplatelet therapy is necessary. However, the combination of oral anticoagulation and antiplatelet therapy increases the bleeding risk. Risk scores such as the CHA2DS2-Vasc score and the HAS-BLED score help to identify both bleeding and stroke risk in individual patients. The guidelines of the European Society of Cardiology provide a rather detailed recommendation for patients on oral anticoagulation after coronary stent implantation. However, robust evidence is lacking for some of the recommendations, and especially for new oral anticoagulants and new antiplatelets few or no data are available. This review addresses some of the critical points of the guidelines and discusses potential advantages of new anticoagulants in patients with atrial fibrillation after stent implantation.

scholarly journals Use of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy After Coronary Stent

2021 ◽  
Vol 35 ◽  
pp. 248-253
Author(s):  
Pham Nhu Hung ◽  
Nguyen Thi Thanh Loan
Keyword(s):  
Antiplatelet Therapy ◽  
Stent Placement ◽  
Dual Antiplatelet Therapy ◽  
Area Under The Curve ◽  
Coronary Stent ◽  
Severe Bleeding ◽  
Post Procedure ◽  
Bleeding Area

Objectives: Use of the HAS-BLED score in risk stratifying patients on dual antiplatelet therapy after stent placement. Methods & Results: 304 patients who underwent stent placement from June, 2018 to December 2018. There is 6,57% patients with medium & severe bleeding. Area under the curve of HAS-BLED score (AUC); PRECISE-DAPT score and CRUSADE were sequential 0.59; 0,79 and 0,84 (p=0,0001) at post-PCI procedures; were sequential 0,72; 0,94 và 0,88 (p=0,00001) at less than 6 months after PCI procedures, and were sequential 0,87; 0,73 và 0,70 (p=0,0068) at more than 6 months after PCI procedures.     Conclusion: the HAS-BLED score was most useful for predicting bleeding in patients on on dual antiplatelet therapy after stent placement at more than 6 months after PCI procedures. PRECISE-DAPT score was most useful for predicting bleeding at less than 6 months after PCI procedures and CRUSADE score was most useful for predicting bleeding at post procedure.

scholarly journals Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data

2020 ◽  
Vol 9 (4) ◽  
Author(s):  
Sanket S. Dhruva ◽  
Craig S. Parzynski ◽  
Ginger M. Gamble ◽  
Jeptha P. Curtis ◽  
Nihar R. Desai ◽  
...  
Keyword(s):  
Adverse Events ◽  
Stent Placement ◽  
Claims Data ◽  
Coronary Stent ◽  
Administrative Claims ◽  
Administrative Claims Data

Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report

2020 ◽  
Vol 19 (3) ◽  
pp. 335-339 ◽  
Author(s):  
Gianfranco Calogiuri ◽  
Eustachio Nettis ◽  
Alessandro Mandurino-Mirizzi ◽  
Elisabetta Di Leo ◽  
Luigi Macchia ◽  
...  
Keyword(s):  
Case Report ◽  
Stent Placement ◽  
Coronary Stent ◽  
Drug Induced

The anti-IgE Omalizumab may be helpful to treat clopidogrel hypersensitivity without stopping thienopyridine administration in patients requirining continuous antiplatellet therapy after coronary stent placement.

Use of Prasugrel in a Patient with Clopidogrel Hypersensitivity

2011 ◽  
Vol 45 (10) ◽  
pp. 1307-1307 ◽  
Author(s):  
Sarah R Peppard ◽  
Bethanne M Held-Godgluck ◽  
Richard Beddingfield
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Stent Placement ◽  
Coronary Intervention ◽  
Bare Metal Stent ◽  
Coronary Stent ◽  
Bare Metal ◽  
Metal Stent ◽  
Therapeutic Alternative ◽  
Percutaneous Coronary ◽  
Hands And Feet

Objective: To report a case of successful use of prasugrel following percutaneous coronary intervention with placement of a bare metal stent in a patient with a documented hypersensitivity reaction to clopidogrel. Case Summary: A 61-year-old male with a history of coronary artery disease with coronary stent placement presented with ST-elevation myocardial infarction. The patient had developed Stephens-Johnson syndrome 6 years earlier following Clopidogrel administration, characterized by erythematous plaques and subsequent desquamation of the hands and feet; Clopidogrel was discontinued and he was subsequently treated with ticlopidine in addition to aspirin. The third-generation thienopyridine prasugrel was initiated as a therapeutic alternative to Clopidogrel after placement of a bare metal stent; a 60-mg dose was administered after extubation, followed by 10 mg/day. No signs of allergic reaction were observed in the days, weeks, and months following administration. Discussion: Thienopyridines, specifically Clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents. One study demonstrated that 27% of patients who developed an allergic or hematologic reaction to Clopidogrel developed a similar reaction to ticlopidine. Other therapeutic options for patients with Clopidogrel hypersensitivity who are undergoing a percutaneous coronary intervention with stent placement include Clopidogrel desensitization, warfarin plus aspirin, cilostazol, ticagrelor, and ticlopidine. However, these options are limited by efficacy and/or toxicity. With its approval in 2009, prasugrel has become a potential treatment option. Conclusions: Prasugrel may be considered a therapeutic alternative in some patients allergic or intolerant to Clopidogrel, but additional data are warranted to make a strong conclusion.

Sign in / Sign up

Export Citation Format

Share Document